ADVERTISEMENT

Analysis

Strategic Surprises: The Drugs That Rewrote The Forecasts

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Oncology’s Most Eligible Unpartnered Assets

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Oncology’s Most Eligible Unpartnered Assets

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

AstraZeneca Leads The Way In Clinical Trials

The UK group began more clinical trials last year than any other company, a new report from Citeline has found.